|
Gene: ENAM |
Gene summary for ENAM |
Gene summary. |
Gene information | Species | Human | Gene symbol | ENAM | Gene ID | 10117 |
Gene name | enamelin | |
Gene Alias | ADAI | |
Cytomap | 4q13.3 | |
Gene Type | protein-coding | GO ID | GO:0002065 | UniProtAcc | Q9NRM1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10117 | ENAM | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 3.71e-02 | 5.24e-01 | 0.159 |
10117 | ENAM | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 2.46e-15 | 1.45e+00 | 0.1479 |
10117 | ENAM | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 3.78e-07 | 9.10e-01 | 0.1531 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Prostate | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ENAM | SNV | Missense_Mutation | c.1553N>G | p.Lys518Arg | p.K518R | Q9NRM1 | protein_coding | deleterious(0.03) | probably_damaging(0.955) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ENAM | SNV | Missense_Mutation | c.2441C>T | p.Pro814Leu | p.P814L | Q9NRM1 | protein_coding | deleterious(0.03) | possibly_damaging(0.86) | TCGA-F4-6808-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ENAM | SNV | Missense_Mutation | c.2276N>C | p.Leu759Pro | p.L759P | Q9NRM1 | protein_coding | tolerated(0.19) | benign(0.043) | TCGA-F4-6809-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ENAM | SNV | Missense_Mutation | c.1855N>G | p.Thr619Ala | p.T619A | Q9NRM1 | protein_coding | tolerated(0.24) | benign(0.03) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
ENAM | SNV | Missense_Mutation | rs747987620 | c.2695N>A | p.Ala899Thr | p.A899T | Q9NRM1 | protein_coding | tolerated(0.07) | possibly_damaging(0.615) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ENAM | SNV | Missense_Mutation | rs200947570 | c.559C>T | p.Arg187Cys | p.R187C | Q9NRM1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AG-3728-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR |
ENAM | SNV | Missense_Mutation | rs143134915 | c.1118G>A | p.Arg373His | p.R373H | Q9NRM1 | protein_coding | tolerated(0.15) | benign(0.029) | TCGA-AG-3878-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ENAM | SNV | Missense_Mutation | c.1454T>G | p.Phe485Cys | p.F485C | Q9NRM1 | protein_coding | deleterious(0.02) | probably_damaging(0.981) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ENAM | SNV | Missense_Mutation | c.2829N>G | p.Asn943Lys | p.N943K | Q9NRM1 | protein_coding | tolerated(0.07) | probably_damaging(0.956) | TCGA-AG-A014-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ENAM | SNV | Missense_Mutation | c.1397T>C | p.Val466Ala | p.V466A | Q9NRM1 | protein_coding | tolerated(0.23) | benign(0.075) | TCGA-AG-A01J-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |